Omalizumab in the treatment of Morbihan syndrome in an adolescent girl - case report and literature review
We present the case of an adolescent girl with MS nonresponding to 19 months of isotretinoin treatment with add-on antihistamines. Therapy with monthly administration of omalizumab (anti-IgE) for 6 months was an effective therapeutic option, improving the quality of life. Our case is the second description of omalizumab use in Morbihan syndrome, the first in an adolescent.PMID:38459887 | DOI:10.15586/aei.v52i2.978 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Zofia Mazurek-Durlak Katarzyna Mularczyk Przemko Kwinta Grzegorz Lis Ewa Cichocka-Jarosz Source Type: research
Omalizumab in the treatment of Morbihan syndrome in an adolescent girl - case report and literature review
We present the case of an adolescent girl with MS nonresponding to 19 months of isotretinoin treatment with add-on antihistamines. Therapy with monthly administration of omalizumab (anti-IgE) for 6 months was an effective therapeutic option, improving the quality of life. Our case is the second description of omalizumab use in Morbihan syndrome, the first in an adolescent.PMID:38459887 | DOI:10.15586/aei.v52i2.978 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Zofia Mazurek-Durlak Katarzyna Mularczyk Przemko Kwinta Grzegorz Lis Ewa Cichocka-Jarosz Source Type: research
Omalizumab in the treatment of Morbihan syndrome in an adolescent girl - case report and literature review
We present the case of an adolescent girl with MS nonresponding to 19 months of isotretinoin treatment with add-on antihistamines. Therapy with monthly administration of omalizumab (anti-IgE) for 6 months was an effective therapeutic option, improving the quality of life. Our case is the second description of omalizumab use in Morbihan syndrome, the first in an adolescent.PMID:38459887 | DOI:10.15586/aei.v52i2.978 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Zofia Mazurek-Durlak Katarzyna Mularczyk Przemko Kwinta Grzegorz Lis Ewa Cichocka-Jarosz Source Type: research
Solar urticaria and omalizumab. A retrospective case-control study and follow-up
Actas Dermosifiliogr. 2024 Mar 5:S0001-7310(24)00182-0. doi: 10.1016/j.ad.2023.04.044. Online ahead of print.NO ABSTRACTPMID:38452893 | DOI:10.1016/j.ad.2023.04.044 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - March 7, 2024 Category: Dermatology Authors: A Casanova-Esquembre J Lorca-Spr öhnle R Pe ñuelas-Leal Amparo P érez-Ferriols Source Type: research
Solar urticaria and omalizumab. A retrospective case-control study and follow-up
Actas Dermosifiliogr. 2024 Mar 5:S0001-7310(24)00182-0. doi: 10.1016/j.ad.2023.04.044. Online ahead of print.NO ABSTRACTPMID:38452893 | DOI:10.1016/j.ad.2023.04.044 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - March 7, 2024 Category: Dermatology Authors: A Casanova-Esquembre J Lorca-Spr öhnle R Pe ñuelas-Leal Amparo P érez-Ferriols Source Type: research
Solar urticaria and omalizumab. A retrospective case-control study and follow-up
Actas Dermosifiliogr. 2024 Mar 5:S0001-7310(24)00182-0. doi: 10.1016/j.ad.2023.04.044. Online ahead of print.NO ABSTRACTPMID:38452893 | DOI:10.1016/j.ad.2023.04.044 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - March 7, 2024 Category: Dermatology Authors: A Casanova-Esquembre J Lorca-Spr öhnle R Pe ñuelas-Leal Amparo P érez-Ferriols Source Type: research
Solar urticaria and omalizumab. A retrospective case-control study and follow-up
Actas Dermosifiliogr. 2024 Mar 5:S0001-7310(24)00182-0. doi: 10.1016/j.ad.2023.04.044. Online ahead of print.NO ABSTRACTPMID:38452893 | DOI:10.1016/j.ad.2023.04.044 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - March 7, 2024 Category: Dermatology Authors: A Casanova-Esquembre J Lorca-Spr öhnle R Pe ñuelas-Leal Amparo P érez-Ferriols Source Type: research
Solar urticaria and omalizumab. A retrospective case-control study and follow-up
Actas Dermosifiliogr. 2024 Mar 5:S0001-7310(24)00182-0. doi: 10.1016/j.ad.2023.04.044. Online ahead of print.NO ABSTRACTPMID:38452893 | DOI:10.1016/j.ad.2023.04.044 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - March 7, 2024 Category: Dermatology Authors: A Casanova-Esquembre J Lorca-Spr öhnle R Pe ñuelas-Leal Amparo P érez-Ferriols Source Type: research
FDA Greenlights First Treatment for Severe Food Allergies
The US Food and Drug Administration (FDA) approved omalizumab, marketed as Xolair, to treat various food allergies in people aged 1 year or older. Omalizumab is a monoclonal antibody that blocks immunoglobulin E, a protein that triggers allergic reactions, including severe ones like anaphylaxis. The FDA first approved the drug in 2003 for treating allergic asthma. (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - March 6, 2024 Category: General Medicine Source Type: research
Eosinophilic gastritis and gluten-sensitive enteropathy manifested as hypoproteinemia and treated with omalizumab: a case report
Eosinophilic gastritis (EoG) has rarely been reported in conjunction with gluten-sensitive enteropathy (GSE). When this does occur, patients typically present with gastrointestinal symptoms. To our knowledge, ... (Source: Allergy, Asthma and Clinical Immunology)
Source: Allergy, Asthma and Clinical Immunology - March 5, 2024 Category: Allergy & Immunology Authors: Zhirong Du, Zixi Wang, Weixun Zhou, Jia Yin and Yuxiang Zhi Tags: Case report Source Type: research
Mepolizumab/omalizumab
(Source: Reactions Weekly)
Source: Reactions Weekly - March 1, 2024 Category: Drugs & Pharmacology Source Type: research
Shedding light on dermographism: a narrative review
Int J Dermatol. 2024 Feb 28. doi: 10.1111/ijd.17102. Online ahead of print.ABSTRACTDermographism is a common subtype of chronic urticaria. It generally manifests as a linear wheal after scratching or friction, with or without angioedema. The pathophysiology is not clear, but currently, we believe that the stimulation of the skin by mechanical stress leads to the activation of mast cells, which provoke the release of histamine and pro-inflammatory mediators, ultimately forming wheal along the stressed area. The gold standard for diagnosis is a medical history and provocation test or dermatographic test. As one of the subtyp...
Source: Cancer Control - February 29, 2024 Category: Cancer & Oncology Authors: Li Zhang Cong Peng Jie Li Source Type: research
Comparison of the therapeutic effects of medication therapy, specific immunotherapy and anti-IgE (Omalizumab) in patients with hay fever
ConclusionOmalizumab and SCIT offer superior effects than medication therapy in hay fever patients. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - February 28, 2024 Category: Allergy & Immunology Source Type: research
‘Breakthrough’ allergy drug: injection protects against severe food reactions
Nature, Published online: 26 February 2024; doi:10.1038/d41586-024-00586-8A study suggests that the asthma treatment omalizumab can reduce the risk of dangerous allergic reactions to peanuts and other foods. (Source: Nature AOP)
Source: Nature AOP - February 26, 2024 Category: Research Authors: Sara Reardon Source Type: research
